AtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.20), $0.10 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $98.3 million versus the consensus estimate of $96.73 million.

GUIDANCE:

AtriCure sees FY2023 EPS of ($0.74)-($0.76), versus the consensus of ($0.92). AtriCure sees FY2023 revenue of $394-396 million, versus the consensus of $393.8 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.